New Prospective for the Management of Low-Risk Pulmonary Embolism: Prognostic Assessment, Early Discharge, and Single-Drug Therapy with New Oral Anticoagulants
Table 4
Ongoing phase III trials on acute treatment of pulmonary embolism.
Study
Patients
Intervention
Comparison
AMPLIFY
Acute symptomatic VTE
Apixaban: 10 mg bid for 7 days then 5 mg bid
Enoxaparin and dose-adjusted warfarin (INR 2.0 to 3.0)
HOKUSAI-VTE
Acute symptomatic VTE, who were initially given parenteral anticoagulation therapy
